PUT - SPRINTER OPEN END - BIOGEN IDEC | Delayed Deutsche Boerse AG 08:31:43 17/05/2024 pm IST | ||
| 17.35 EUR | +0.46% |
|
| Current month | -7.94% | ||
| 1 month | -16.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 17.35 | +0.46% |
| 16/24/16 | 17.27 | +3.66% |
| 15/24/15 | 16.66 | -6.03% |
| 14/24/14 | 17.73 | -0.67% |
| 13/24/13 | 17.85 | -1.16% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 08:31 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VQ8LE7 |
| ISIN | DE000VQ8LE75 |
| Date issued | 11/06/2021 |
| Strike | 414.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.45 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.14 € |
|---|---|
| Lowest since issue | 1.46 € |
| Spread | 0.03 € |
| Spread % | 0.17% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230
USD
Average target price
285.9
USD
Spread / Average Target
+24.29%
- Stock Market
- Certificates
- Certificat